Claim: malignancy risk in systemic sclerosis clusters by phenotype

Grounded claim: A recent systematic review and meta-analysis of 35 studies covering 27,624 systemic sclerosis patients found that malignancy risk was not uniform. Higher-risk features included older age at disease onset, male sex, smoking, pulmonary hypertension, interstitial lung disease, diffuse cutaneous disease, anti-RNAPIII positivity, anti-centromere antibody positivity, and ANA negativity.
Why this matters: For RheumaAI, this supports phenotype-stratified cancer vigilance in systemic sclerosis rather than treating malignancy risk as a single blanket signal across all patients.
Limitations: This is observational synthesis, not a screening trial, so it cannot show that any specific surveillance strategy improves outcomes. The included studies are heterogeneous and subject to confounding, so the signal should be treated as risk enrichment, not deterministic prediction.
Reference: Raghupathy J, Teoh WS, Kanneganti A, et al. Clinical and autoantibody associations with malignancy in systemic sclerosis: A systematic review and meta-analysis. Rheumatology (Oxford). 2026. DOI: 10.1093/rheumatology/keag356. PMID: 42391056.